Table 2.
Effect of Bifidobacteria and LPS co-treatment on pro-inflammatory cytokine production by murine macrophages.
| Strain | Pro-inflammatory cytokine production | |||||
|---|---|---|---|---|---|---|
| TNF-α (pg/ml) | IL-1β (pg/ml) | IL-6 (ng/ml) | ||||
| RAW 264.7 cells + Bif | RAW 264.7 cells + LPS + Bif | RAW 264.7 cells + Bif | RAW 264.7 cells + LPS + Bif | RAW 264.7 cells + Bif | RAW 264.7 cells + LPS + Bif | |
| B. longum Bif 4 | 2115 ± 78* | 2402 ± 5.9# | 60.4 ± 2.5* | 93.3 ± 6.9# | 14.6 ± 0.9* | 48.9 ± 0.1# |
| B. longum Bif 6 | 34.3 ± 9.3 | 47.2 ± 12# | 22.5 ± 1.5* | 18.7 ± 3.8# | 3.3 ± 0.3 | 12.1 ± 0.6# |
| B. longum Bif 10 | 50 ± 11.3 | 50.5 ± 12# | 19.7 ± 0.2* | 21.2 ± 3.6# | 2.7 ± 0.4 | 3.11 ± 0.2# |
| B. breve Bif 11 | 72 ± 12.1* | 60.6 ± 19.8# | 29.1 ± 1.7* | 22.5 ± 6.3# | 3.9 ± 1.3 | 42.1 ± 1.8# |
| B. longum Bif 12 | 46 ± 15.5 | 98.8 ± 7.3# | 8.4 ± 2.7 | 9.6 ± 3.9# | 3.2 ± 0.2 | 9.7 ± 0.1# |
| B. longum Bif 14 | 28.6 ± 1.3 | 64.8 ± 0.6# | 12.4 ± 4.6 | 33.1 ± 5.2# | 8.1 ± 0.3 | 16.6 ± 1.7# |
| B. longum Bif 16 | 32.1 ± 6.1 | 82.6 ± 9.8# | 4.4 ± 0.7 | 18.8 ± 4.9# | 4.4 ± 0.1 | 6.7 ± 0.4# |
| B. longum Bif 17 | 27 ± 6.0 | 121.5 ± 27# | 18.7 ± 4.6 | 24 ± 1.16# | 6.0 ± 0.2 | 18.1 ± 1.2# |
| B. longum Bif 20 | 40.4 ± 0.1 | 141.2 ± 51.6# | 11.6 ± 2.5 | 23.4 ± 1.1# | 9.5 ± 0.1 | 61.2 ± 6.8# |
| B. longum Bif 29 | 209 ± 65.4 | 226.8 ± 57.3# | 19.7 ± 4.6 | 26.4 ± 4.5# | 5.6 ± 0.6 | 19.3 ± 2.6# |
| B. longum Bif 30 | 91 ± 22.1 | 392 ± 48.1# | 22.4 ± 4.8 | 26.4 ± 5.3# | 5.7 ± 1.6 | 24.8 ± 2.4# |
| B. breve Bif 40 | 77 ± 26.5 | 100 ± 3.2# | 24.1 ± 0.4 | 19.7 ± 3.3# | 4.0 ± 0.3 | 11.4 ± 1.6# |
Control was untreated RAW cells; LPS control was RAW cells treated with 1 μg/ml LPS. TNF-α, IL-1β and IL-6 for untreated RAW cells were 48.5 ± 14.7 pg/ml; 3.0 ± 0.1 pg/ml and 4.9 ± 3.1 ng/ml respectively while that of LPS treated RAW cells were 4573 ± 58.8 pg/ml; 170 ± 4.5 pg/ml; 166.6 ± 10.9 pg/ml respectively.
Data was analyzed using one-way ANOVA followed by Tukey’s Post-hoc test (p ≤ 0.05). #significant relative to LPS treatment; *significant relative to untreated control (N = 4).